Prostate Cancer Trial, Recruiting NCT06219746 Sponsor: Turku University Hospital Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06219746
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give written consent and follow the study requirements
  • People who are male and aged 18 or older at the start of the study
  • People who have been diagnosed with high-risk prostate cancer confirmed by a tissue sample, meeting at least one of the following: a Gleason score of 4+4 or higher (a measure of how aggressive the cancer appears under a microscope), a PSA level of 20 or above (a protein measured in the blood related to prostate cancer), or a tumour stage of cT3a or higher (confirm with trial site)

Who may not be able to join:

  • People who have a known allergy or sensitivity to the study medications or their ingredients
  • People who are unable to provide written consent
  • People who have another significant illness or condition that, in the trial doctor's judgment, could put them at risk or affect the study results
  • People who have a history of drug or alcohol use that, in the trial doctor's judgment, could make it difficult to follow the study requirements
  • People who have already started hormone therapy (androgen deprivation therapy) to reduce testosterone before joining the trial
  • People who experience claustrophobia (fear of enclosed spaces), which may be relevant to certain scans used in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Turku University Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
31 December 2024

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Number of subjects with local lymph node metastasi(e)s

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov